0.8449

2.02% 0.0167

Longeveron Inc (LGVN)

Overview News Price History Financials Why LGVN Down? Discussions Forecast

Longeveron Inc stock is traded at $0.8449, with a volume of 768.63K. It is up +2.02% in the last 24 hours and up +38.15% over the past month. Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Previous Close:

$0.8282

Open:

$0.86

24h Volume:

768.63K

Relative Volume:

2.19

Market Cap:

$26.94M

Revenue:

$1.22M

Net Income/Loss:

$-22.43M

P/E Ratio:

-0.7306

EPS:

-1.1564

Net Cash Flow:

$-18.78M

1W Performance:

+14.19%

1M Performance:

+38.15%

6M Performance:

+46.91%

1Y Performance:

+5.61%

1-Day Range:

$0.8231

$0.87

1-Week Range:

$0.74

$0.89

52-Week Range:

$0.475

$1.23

Longeveron Inc Stock (LGVN) Company Profile

Name

Longeveron Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

305-302-7158

Address

1951 NW 7TH AVENUE, MIAMI

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

LGVN's Discussions on Twitter

Compare LGVN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGVN Longeveron Inc	0.8449	26.40M	1.22M	-22.43M	-18.78M	-1.1564
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	ROTH MKM	Buy

Longeveron Inc Stock (LGVN) Latest News

Aug 21, 2026

Longeveron (LGVN) Earnings Reading: Profit Per Share Falls Below Its Benchmark at the Close; After Results: The Stock Gains 4.46% in the Current UpdateProfitability Analysis - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Longeveron appoints Nirav Jhaveri as chief financial officer - Investing.com Nigeria

Aug 19, 2026

Longeveron Appoints Nirav Jhaveri as CFO Ahead of September Trial Data - Minichart

Aug 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 19, 2026

Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed - TipRanks

Aug 19, 2026

Longeveron Appoints New Chief Financial Officer Jhaveri - TipRanks

Aug 19, 2026

Longeveron Appoints Nirav Jhaveri As CFO - marketscreener.com

Aug 19, 2026

Longeveron appoints Nirav Jhaveri as chief financial officer By Investing.com - Investing.com India

Aug 19, 2026

Longeveron Inc. Appoints Nirav Jhaveri as Chief Financial Officer - Quiver Quantitative

Aug 19, 2026

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer - Yahoo Finance

Aug 19, 2026

Aug 18, 2026

Marie Washburn Net Worth (2026) - GuruFocus

Aug 18, 2026

Aug 17, 2026

Longeveron reports Q2 EPS (19c) vs. (33c) last year - TipRanks

Aug 17, 2026

$Longeveron (LGVN.US)$ - Moomoo

Aug 17, 2026

Aug 15, 2026

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits

Aug 15, 2026

Aug 14, 2026

Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us

Aug 14, 2026

Aug 13, 2026